Rational Discovery of Dual-Action Multi-Target Kinase Inhibitor for Precision Anti-Cancer Therapy Using Structural Systems Pharmacology

Abstract

AbstractAlthough remarkable progresses have been made in the cancer treatment, existing anti-cancer drugs are associated with increasing risk of heart failure, variable drug response, and acquired drug resistance. To address these challenges, for the first time, we develop a novel genome-scale multi-target screening platform 3D-REMAP that integrates data from structural genomics and chemical genomics as well as synthesize methods from structural bioinformatics, biophysics, and machine learning. 3D-REMAP enables us to discover marked drugs for dual-action agents that can both reduce the risk of heart failure and present anti-cancer activity. 3D-REMAP predicts that levosimendan, a drug for heart failure, inhibits serine/threonine-protein kinase RIOK1 and other kinases. Subsequent experiments confirm this prediction, and suggest that levosimendan is active against multiple cancers, notably lymphoma, through the direct inhibition of RIOK1 and RNA processing pathway. We further develop machine learning models to identify cancer cell-lines and patients that may respond to levosimendan. Our findings suggest that levosimendan can be a promising novel lead compound for the development of safe and effective multi-targeted cancer therapy, and demonstrate the potential of genome-wide multi-target screening in designing polypharmacology and drug repurposing for precision medicine.Author SummaryMulti-target drug design (a.k.a targeted polypharmacology) has emerged as a new strategy for discovering novel therapeutics that can enhance therapeutic efficacy and overcome drug resistance in tackling multi-genic diseases such as cancer. However, it is extremely challenging for conventional computational tools that are either receptor-based or ligand-based to screen compounds for selectively targeting multiple receptors. Existing multi-target drug design mainly focuses on compound screening against receptors within the same gene family but not across different gene families. Here, we develop a new computational tool 3D-REMAP that enables us to identify chemical-protein interactions across fold space on a genome scale. The genome-scale chemical-protein interaction network allows us to discover dual-action drugs that can bind to two types of targets simultaneously, one for mitigating side effect and another for enhancing the therapeutic effect. Using 3D-REMAP, we predict and subsequently experiments validate that levosimendan, a drug for heart failure, is active against multiple cancers, notably, lymphoma. This study demonstrates the potential of genome-wide multi-target screening in designing polypharmacology and drug repurposing for precision medicine.